Ligand has assembled one of the largest portfolios of biopharmaceutical assets among our peers which provides investors the opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company.
| Program | Partner | Indication | Technology | Development Stage | |||||
|---|---|---|---|---|---|---|---|---|---|
| Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA | Marketed | ||||
| VFEND | Pfizer | Infectious Disease | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 Complete
|
NDA Complete
|
Marketed In Progress
|
| Noxafil-IV | Merck | Infectious Disease | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 Complete
|
NDA Complete
|
Marketed In Progress
|
| Carnexiv | Lundbeck | CNS | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 Complete
|
NDA Complete
|
Marketed In Progress
|
| Interferon beta-1a | Biocad | Inflammation/Metabolic | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 Complete
|
NDA Complete
|
Marketed In Progress
|
| Promacta | Novartis | Blood Disorders | Other |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 Complete
|
NDA Complete
|
Marketed In Progress
|
| Baxdela | Melinta | Infectious Disease | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 Complete
|
NDA Complete
|
Marketed In Progress
|
| Vivitra | Zydus Cadila | Inflammation/Metabolic | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 Complete
|
NDA Complete
|
Marketed In Progress
|
| Nexterone | Baxter | Cardiovascular | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 Complete
|
NDA Complete
|
Marketed In Progress
|
| Duavee | Pfizer | Inflammation/Metabolic | Other |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 Complete
|
NDA Complete
|
Marketed In Progress
|
| Exemptia | Zydus Cadila | Inflammation/Metabolic | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 Complete
|
NDA Complete
|
Marketed In Progress
|
| Viviant/Conbriza | Pfizer | Inflammation/Metabolic | Other |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 Complete
|
NDA Complete
|
Marketed In Progress
|
| Voriconazole | Alvogen | Infectious Disease | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 Complete
|
NDA Complete
|
Marketed In Progress
|
| Kyprolis | Amgen | Cancer | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 Complete
|
NDA Complete
|
Marketed In Progress
|
| EVOMELA | Spectrum | Cancer | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 Complete
|
NDA Complete
|
Marketed In Progress
|
| CE-Fosphenytoin | Sedor | CNS | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 Complete
|
NDA In Progress
|
Marketed Not Started
|
| Brexanolone (SAGE-547) | SAGE | CNS | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 In Progress
|
NDA Not Started
|
Marketed Not Started
|
| CS-3150 | Exelixis / Daiichi-Sankyo | Cardiovascular | Other |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 In Progress
|
NDA Not Started
|
Marketed Not Started
|
| BCD-066 | Biocad | Blood Disorders | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 In Progress
|
NDA Not Started
|
Marketed Not Started
|
| ONS-1045 | Oncobiologics | Cancer | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 In Progress
|
NDA Not Started
|
Marketed Not Started
|
| CHS-0214 | Coherus | Inflammation/Metabolic | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 In Progress
|
NDA Not Started
|
Marketed Not Started
|
| ONS-3010 | Oncobiologics | Cancer | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 In Progress
|
NDA Not Started
|
Marketed Not Started
|
| Verubecestat | Merck | CNS | Other |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 In Progress
|
NDA Not Started
|
Marketed Not Started
|
| Promacta (MDS/AML) | Novartis | Cancer | Other |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 In Progress
|
NDA Not Started
|
Marketed Not Started
|
| SAR125844 | Sanofi | Cancer | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| ADX-102 (NS-2) | Aldeyra | Other/Undisclosed | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| VK5211 | Viking | Inflammation/Metabolic | Other |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| BMS986231 (CXL-1427) | Cardioxyl / BMS | Cardiovascular | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| Aplindore | Seelos Therapeutics | CNS | Other |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| TR Beta | Viking | Inflammation/Metabolic | Other |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| BAX-69 | Baxter | Cancer | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| Lubricin | Lubris | Inflammation/Metabolic | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| RVT-1502 | Roivant Sciences | Inflammatory/Metabolic | Other |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| hCDR1 | XTL Bio | Severe and Rare | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OPT-302 | Opthea | Other/Undisclosed | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| VX-970 | Merck KGaA | Cancer | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| VK0612 | Viking | Inflammation/Metabolic | Other |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| VTX-2337 | VentiRx | Cancer | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| Prexasertib (LY2606368) | Eli Lilly | Cancer | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| Sparsentan | Retrophin | Severe and Rare | Other |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| MM-141 | Merrimack | Cancer | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| KLM465 ('5921) | Novartis | Blood Disorders | Other |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| MLN-4924 | Millennium / Takeda | Cancer | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| Lasofoxifene | Sermonix | Inflammation/Metabolic | Other |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| Promacta (CIT) | Novartis | Blood Disorders | Other |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| MM-121 | Merrimack | Cancer | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| NPC-1C | Precision Biologics | Cancer | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| ODSH | Cantex | Cancer | Other |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| GNR-008 | IBC Generium | Severe and Rare | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| TAK-020 | Takeda | Inflammation/Metabolic | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| UC-961 | ROAR Therapeutics | Cancer | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| Deplera | IBC Generium | Cancer | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| F-102 | F-Star | Cancer | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| Merestinib | Eli Lilly | Cancer | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| LY3023703 | Eli Lilly | CNS | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| Altiratinib | Deciphera | Cancer | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| AMG-330 | Amgen | Cancer | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| Trametinib | Novartis | Cancer | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| CXCR4 | Upsher Smith | Cancer | Other |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| GS-5734 | Gilead | Infectious Disease | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| Pradefovir | Chiva | Infectious Disease | Other |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| ME-143 | MEI | Cancer | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| ME-344 | MEI | Cancer | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| CE-Budesonide | Sedor | Inflammation/Metabolic | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| IV Topiramate | CURx | CNS | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| MB07133 | Chiva | Cancer | Other |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OPC-269 | Otsuka | Cardiovascular | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| EPOR Agonist | Biocad | Blood Disorders | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| Trastuzumab | Gedeon Richter | Cancer | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| Bevacizumab | Gedeon Richter | Cancer | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| VTX-1463 | VentiRx | Cancer | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| RGB-03 | Gedeon Richter | Inflammation/Metabolic | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| MM-151 | Merrimack | Cancer | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| XL652 | Exelixis / Daiichi-Sankyo | Cardiovascular | Other |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OmniAb | Stemcentrx / AbbVie | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OmniAb | WuXi | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OmniAb | Seattle Genetics | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OmniAb | Symphogen | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OmniAb | Hanall | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OmniAb | Teneobio | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OmniAb | Gilead | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OmniAb | Janssen | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OmniAb | Merck KGaA | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OmniAb | Pfizer | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| NUC-101 | Nucorion | Infectious Disease | Other |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| NUC-202 | Nucorion | Infectious Disease | Other |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| NUC-404 | Nucorion | Cancer | Other |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| H3 Receptor Antagonist | Seelos Therapeutics | Inflammation/Metabolic | Other |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| CE programs | Avion | Other/Undisclosed | Captisol |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OmniAb | Genmab | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| LRP-6 | Merck KGaA | Cancer | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OmniAb | Tizona | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| PDL-1 antibody | C-Stone | Cancer | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| PD-1 antibody | Gloria | Cancer | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| FGFR1 | Merck KGaA | Cancer | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OmniAb | Teva | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OmniAb | ABBA | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| LTP-O3FA | Omthera / AstraZeneca | Inflammation/Metabolic | Other |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| IRAK4 | TG Therapeutics | Cancer | Other |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| Ganaxalone IV | Marinus | CNS | Captisol |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| CE-Propofol | Cuda | CNS | Captisol |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| SAGE-689 | SAGE | CNS | Captisol |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| Lasofoxifene | Azure | Inflammation/Metabolic | Other |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| EPOR Agonist | Viking | Blood Disorders | Other |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| DGAT-1 Inhibitor | Viking | Inflammation/Metabolic | Other |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| CE-Meloxicam | Sedor | Inflammation/Metabolic | Captisol |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| ML-061 | Meridian | Cancer | Captisol |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| IV Lamotrigine | CURx | CNS | Captisol |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| Cantrixil | Novogen | Cancer | Captisol |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OmniAb | ARMO | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OmniAb | Celgene | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OmniAb | Aptevo Therapeutics | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OmniAb | F-Star | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OmniAb | Amgen | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| CE - Cannibinoids | Vireo Health | Inflammation/Metabolic | Captisol |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| Rituximab | Oncobiologics | Cancer | Selexis SUREtechnology |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| ONS-1050 | Oncobiologics | Cancer | Selexis SUREtechnology |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| Undisclosed | AiCuris | Infectious Disease | Captisol |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
| OmniAb | Five Prime | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 Not Started
|
NDA Not Started
|
Marketed Not Started
|
